What changed: Colon cancer (adenocarcinoma of the colon)

When this page itself was last checked or edited.

3-year recurrence HR 0.

3-year DFS 86.

DFS HR 0.

ctDNA is strongly prognostic (three-year recurrence-free survival 87 against 49 percent) but de-escalation was not non-inferior and escalation did not help.

Residual or recurrent disease within two years 16.

Chemotherapy use 15% vs 28% with non-inferior RFS.

pCR 68%, major pathologic response 95%; 3-year DFS 100%.

OS 37.

Relapse-free survival hazard ratio 1.

Peritoneal metastasis-free survival at 18 months 80.

Three months non-inferior to six for CAPOX and for low-risk (T1-3 N1) disease; six months better for T4 or N2.

Three-year disease-free survival 76.

No disease-free survival benefit from cetuximab in KRAS wild-type disease (hazard ratio 1.

Three-year disease-free survival 71.

CRYSTAL KRAS-WT OS 23.

Five-year disease-free survival 56.

Relative risk of death 0.

Adjuvant stage III colon cancer (oxaliplatin, MOSAIC)

Adjuvant stage III colon cancer

Three-year disease-free survival 78.